#United States #New York #Immunic #IMUX #Neurologic Diseases

Immunic's Upcoming Engagements in Investor Conferences

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company specializing in innovative oral therapies for neurologic disorders, is poised to actively participate in several prominent investor conferences throughout November 2026. These sessions aim to provide valuable insights into the company’s ongoing developments and strategic initiatives in treating neurologic diseases.

Conference Schedule

1. Guggenheim 3rd Annual Healthcare Innovation Conference

• - Date: November 9-11, 2026
• - Location: Boston
• - Key Participants: Erik Lundgren (CEO), Jason Tardio (President and COO)

Immunic’s leadership will host a fireside chat on November 9 at 1:00 PM ET. Attendees can follow along via a live webcast available on the Events and Presentations section of Immunic's official website. Additionally, one-on-one investor meetings will be organized, providing an opportunity for detailed discussions with company executives. To arrange a meeting, investors are advised to reach out to their Guggenheim representative or connect directly with Jessica Breu from Immunic.

2. Stifel 2026 Healthcare Conference

• - Date: November 10-12, 2026
• - Location: New York
• - Key Participants: Erik Lundgren, Jason Tardio

The Immunic team will participate again in another fireside chat on November 11 at 2:00 PM ET. Similar to the Guggenheim event, the conference will host a series of one-on-one meetings for investors wishing to engage with the executives. Interested parties can coordinate meetings through their Stifel representatives or by contacting Jessica Breu.

3. Jefferies Global Healthcare Conference

• - Date: November 17-18, 2026
• - Location: London
• - Key Participants: Erik Lundgren, Jason Tardio, and Patrick Walsh (Chief Business Officer)

Here, the executive trio will engage in private meetings aimed at discussing the company’s advancements and future outlook. Investors wishing to facilitate discussions should reach out to Jessica Breu for scheduling.

Virtual Progressive Multiple Sclerosis RD Day

Additionally, on November 5, 2026 at 12:30 PM ET, Immunic will host a virtual event titled Progressive Multiple Sclerosis Research and Development Day. The session will feature presentations from leading specialists in multiple sclerosis, Jiwon Oh, M.D., Ph.D., FRCPC, (University of Toronto) and Maria Pia Sormani, Ph.D., (University of Genoa, Italy).

The discussion will elaborate on unmet needs within the progressive multiple sclerosis spectrum, emphasizing innovative approaches targeting neurodegeneration mechanisms. Those interested in attending the session can register via Immunic’s website.

About Immunic, Inc.

Immunic, Inc. is focused on pioneering oral therapies designed for several neurologic diseases. Among its frontrunner products is vidofludimus calcium (IMU-838), currently undergoing Phase 3 clinical trials for relapsing multiple sclerosis, with data results anticipated by the year’s end. Preparations are underway to initiate an additional Phase 3 trial for progressive multiple sclerosis in late 2026.

Vidofludimus calcium is hoped to integrate neuroprotective qualities associated with nuclear receptor Nurr1 activation, alongside anti-inflammatory and anti-viral properties from inhibiting dihydroorotate dehydrogenase (DHODH). Immunic also aims to build a broader therapeutic platform targeting neurodegenerative and autoimmune conditions through its development pipeline, which includes IMU-381 and IMU-856.

Investors and stakeholders are encouraged to stay informed through company updates, particularly in this crucial phase of development that holds promise for addressing significant health challenges in neurology.

Forward-Looking Statements

This article contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ significantly from projected results. For more details, please refer to Immunic's filings with the SEC.

For more information on Immunic, visit Immunic's website.